Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Buser

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1994
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK)R A Joss, M Bacchi, K Buser, et al.
Nucleic Acids Research|August 11, 1987
The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231S C Kozma, M E Bogaard, K Buser, et al.
Schweizerische Medizinische Wochenschrift|September 5, 1992
[Leiomyosarcoma of the breast 16 years following successful treatment of a rhabdomyosarcoma of the orbit in childhood]K Buser, H J Altermatt, H Ohnacker, et al.
International Journal of Cancer|December 1, 1994
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancerA E Oberli-Schrämmli, F Joncourt, M Stadler, et al.
British Journal of Haematology|September 1, 1993
Cytostatic drug resistance: parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA-alkyltransferase and P-glycoprotein in adult patients with leukaemiaF Joncourt, A Oberli, S M Redmond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiationK Buser, M Bacchi, A Goldhirsch, et al.
British Journal of Cancer|July 1, 1992
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study GroupC Seynaeve, J Schuller, K Buser, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1997
Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinumA du Bois, H J Lück, K Buser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusionE A Eisenhauer, W W ten Bokkel Huinink, K D Swenerton, et al.
Zeitschrift Fur Geburtshilfe Und Neonatologie|January 14, 2005
[Universal hearing screening for babies--recommendations for the organization and performance of the universal screening of babies for hereditary hearing disorders in Germany]M Gross, K Buser, U Freitag, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1994
Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK)R A Joss, M Bacchi, K Buser, et al.
Nucleic Acids Research|August 11, 1987
The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231S C Kozma, M E Bogaard, K Buser, et al.
Schweizerische Medizinische Wochenschrift|September 5, 1992
[Leiomyosarcoma of the breast 16 years following successful treatment of a rhabdomyosarcoma of the orbit in childhood]K Buser, H J Altermatt, H Ohnacker, et al.
International Journal of Cancer|December 1, 1994
Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancerA E Oberli-Schrämmli, F Joncourt, M Stadler, et al.
British Journal of Haematology|September 1, 1993
Cytostatic drug resistance: parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA-alkyltransferase and P-glycoprotein in adult patients with leukaemiaF Joncourt, A Oberli, S M Redmond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiationK Buser, M Bacchi, A Goldhirsch, et al.
British Journal of Cancer|July 1, 1992
Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study GroupC Seynaeve, J Schuller, K Buser, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 1997
Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinumA du Bois, H J Lück, K Buser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1994
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusionE A Eisenhauer, W W ten Bokkel Huinink, K D Swenerton, et al.
Zeitschrift Fur Geburtshilfe Und Neonatologie|January 14, 2005
[Universal hearing screening for babies--recommendations for the organization and performance of the universal screening of babies for hereditary hearing disorders in Germany]M Gross, K Buser, U Freitag, et al.
Pageof 6